Skip to main content
CMPS logo

CMPS · COMPASS Pathways plc

Track CMPS — free
$8.14 +0.02 (+0.25%)
Market Cap
$1.15B
Shares
141.71M
Volume · Nov 19 122.15K Avg daily vol (3M) 3.01M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.12 Open$7.99 Day$7.85–8.22 52W close$4.94–15.19 Avg vol 30d3.4M Short int17.2M · 12.1% of shares · 7.7d Short vol30% Last earningsNov 3, 2026 DataSep 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Feb 4, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 19
Investor event
Comp360 NDA filing completed; company plans launch-ready by year-end

COMPASS Pathways said it has completed the NDA filing for COMP360 for treatment-resistant depression, holds a national priority voucher, and expects the FDA review to conclude within one to two months of submission completion. The company said it will be launch-ready by year-end, with launch expected in the first half of next year subject to approval. It expects COMP360 to require two to four annual doses versus 35 to 55 for Spravato.

6 source passages
So we're very excited that COMPAS has recently completed our filing of COMP360 to the FDA. We have a national priority voucher, which means that we can expect potentially a very rapid approval. We see no reason to suggest that they're slowing down or backtracking on their commitment to try and get this done within the one to two months from us completing our submission. And we have been clearly guiding for some time that we will be ready to launch at the end of the year and expecting a launch in the first half of next year subject to approval. The reason we believe Comp360 is and will become more valuable than Spravato is the fact that Comp360 only requires somewhere between two and four doses on an annualized basis. You compare and contrast that to Spravato, they are somewhere between 35 and 55 doses on an annualized basis. Open the document at this passage
Nov 18
Investor event
COMP360 filing completed; launch-ready by year end

Compass Pathways has completed its FDA filing for COMP360, its synthetic psilocybin for treatment-resistant depression, supported by two Phase III studies enrolling close to 900 patients. It expects to be launch ready by the end of the year and to launch in the first half of next year, subject to approval. Management said about 93% of the population lives in states that will reschedule within 30 days.

5 source passages
COMPAS has recently completed our filing of COMP360 to the FDA. Two Phase III studies, enrolling close to 900 patients between them, highly statistically significant positive results, supported by a very robust Phase IIb. We have committed to and are and will be launch ready by the end of the year, regardless of what happens. and expecting a launch in the first half of next year subject to approval. right now we're sitting with about 93% of the population that will reschedule within 30 days. Open the document at this passage
Nov 11
Investor event
Comp360 NDA submitted, launch targeted by year-end

COMPASS Pathways submitted the Comp360 NDA for treatment-resistant depression, plans to be launch ready by the end of the year, and expects initial revenue in late Q2, Q3 next year.

3 source passages
So first, for those that aren't familiar with Compass Pathways, we are a biotechnology company that... It has been developing a synthetic proprietary formulation of psilocybin that we call Comp360. Earlier this week, we announced that we have completed the submission of our NDA, which we had already been submitting on a rolling basis and has been reviewed on a rolling basis for our lead indication and treatment-resistant depression. We've said very publicly for some time now that we would be launched ready by the end of the year I would not expect a real start of revenue to start happening until probably the Q3, late Q2, Q3 next year. Open the document at this passage
Nov 11
Investor event
NDA completed; launch readiness targeted by end of year

COMPASS Pathways completed its NDA submission for treatment-resistant depression. It targets launch readiness by the end of the year and expects revenue to begin around late Q2 or Q3 next year.

3 source passages
Earlier this week, we announced that we have completed the submission of our NDA, which we had already been submitting on a rolling basis and has been reviewed on a rolling basis for our lead indication and treatment-resistant depression. We've said very publicly for some time now that we would be launched ready by the end of the year, knowing our timelines for when we were going to finalize the NDA submission or about the approximate time of finalizing it, and what the priority review voucher could afford us, and that is what Steve mentioned is that contracted timelines to approval. But I would not expect a real start of revenue to start happening until probably the Q3, late Q2, Q3 next year. Open the document at this passage
Nov 3
Current report 8-K
NDA nearing completion with $444 million cash

COMPASS Pathways said its rolling NDA submission will be filed in the next two weeks, supporting an expected H12027 launch subject to FDA approval. The company ended the third quarter with $444 million in cash, expected to fund operations into 2028.

Financial results
4 source passages
COMPASS PATHWAYS PLC Final NDA submission will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Strong cash position of $444 million at the end of third quarter, providing cash well beyond launch and into 2028 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$266.30M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$392.99M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+70.5%
Year over year · more shares
Price change (1Y)
+50.6%
Trailing year
Short interest
12.1%
Latest settlement · 7.7 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. Compass Pathways reported positive Phase 3 data for COMP360 in TRD with durability through six months and an ongoing rolling NDA submission targeted for completion in Q4, with commercial launch anticipated in the first half of 2027, supported by $433 million in cash expected to fund operations into 2028. Net loss widened sharply to $253.8 million in Q2 from $38.4 million a year ago, driven by $205.6 million in non-cash warrant fair value adjustments.

Bullish
  • + Rolling NDA submission is underway with FDA review in progress and final submission on track for Q4 2026.
  • + Cash position of $433 million is expected to fund operations well beyond launch and into 2028.
  • + Approximately 90% of interventional psychiatrists indicated willingness to prescribe COMP360 within the first year of availability.
  • + R&D expenses declined to $29.2 million in Q2 2026 from $30.3 million in Q2 2025 as Phase 3 costs tapered.
Bearish
  • − Q2 net loss widened sharply to $253.8 million ($1.88/share) from $38.4 million a year earlier, primarily due to a $205.6 million non-cash warrant fair value loss.
  • − G&A expenses rose to $23.2 million in Q2 2026 from $12.6 million a year earlier as commercial preparedness spending ramped.
  • − Launch remains dependent on FDA approval and subsequent DEA and state-level rescheduling, creating timing uncertainty.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −23%
below
Price vs 50-day avg −30%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 31%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −31%
trailing
6-month return −38%
trailing
YTD return +18%
this year
Relative strength −34%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $12 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+6% holders QoQ · +51 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.14% of shares out · ▼ -2.7% MoM · 7.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
241 holders — near 3-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Weak
EPS growth −34%
Y/Y
Free cash flow $-157.2M
Balance sheet $118.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 93%
annualized · 1-yr
Max drawdown −49%
past year
ATR 9.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−23% Bearish
Price vs 50-day avg
−30% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
31% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $12 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+6% holders QoQ · +51 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.14% of shares out · ▼ -2.7% MoM · 7.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
241 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5 Now $8 · 31% Range high $15
vs 200-day avg -23% vs 50-day avg -30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CMPS
COMPASS Pathways plc
this stock
$1.15B +17.7% — — 12.1%
HCA
HCA Healthcare, Inc.
$97.59B +2.0% +7.1% 15.8 2.3%
FSNUY
Fresenius SE & Co. KGaA
$33.07B +2.4% — — 0.0%
THC
Tenet Healthcare Corp
$21.60B +36.5% +0.9% 7.9 2.2%
EHC
Encompass Health Corp
$13.24B +27.1% +10.5% 21.1 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
241
% held
70.6%
Net QoQ
+9.6M sh
Top holder
Deep Track Capital, LP
Held Float
View
Held by Funds
Fund positions
25
View
Short & Settlement
Short Interest Falling
Shares short
17.2M
Days to cover
7.7d
Change
-469.1K sh
View
Short Volume
Short vol %
30%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
170
Value
$2.0K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
50.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Shri Thanedar
Amount
$1.0K–$15.0K
Traded
Jan 23, 2023
View
Financials
Financials
Net income (FY)
$-287.9M
EPS diluted
$-3.08
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 19, 2026
This year
24

COMPASS Pathways said it has completed the NDA filing for COMP360 for treatment-resistant depression, holds a national priority voucher, and expects the FDA review to conclude within one to two months of submission completion. The company said it will be launch-ready by year-end, with launch expected in the first half of next year subject to approval. It expects COMP360 to require two to four annual doses versus 35 to 55 for Spravato.

View
Proposed Sales
Value
$345.8K
Shares
26.0K
Filed
Aug 10, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 19, 2026
View
Investor Relations
Latest news
Compass Pathways to Participate i…
Published
Nov 11, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
CMPS -12.7% -31.4% -37.8% -29.8% +17.7%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -8.8% -25.9% -34.4% -26.4% +10.6%
Key facts CIK 1816590 CUSIP 20451W101 13F (30d) 225 filings 216 filers Visit website Investor relations